The U.K. is advising people under the age of 30 against using AstraZeneca amid concerns about links to rare blood clots. The European regulator believes the vaccine’s benefits still outweigh its risks, except for young people.
Though Britain’s Medicines and Healthcare products Regulatory Agency said more research must be done to understand whether there really is a direct connection to the vaccine and blood clots. According to the British government, 79 severe cases of blood clots were reported in the U.K. out of 20 million doses that were administered. 19 of those individuals died.
Meanwhile, the European Union’s health agency said it had found possible links between the vaccine and blood clots, however, the benefits outweigh the possible risks. The European Medicine Agency said it found no specific risks to clots but, the people that did have clots were primarily under the age of 60 and female.
Numerous countries including Italy, Germany, and France, suspended the use of the vaccine last month, leading to a much slower rollout of the vaccination effort.
Shares of AstraZeneca were under pressure overseas, trading down nearly 1%.